CBD oil – my new migraine wonder weapon

Could CBD be an anitbiotic?

The relationship between infection and conventional prescription antibiotics

Could CBD work in the battle against resistant bacterial strains? The results from the University of Queensland in Australia recommend that it is possible. However before analyzing the study in depth, it is useful to comprehend the evolution of the relationship between germs and prescription antibiotics.

Given that the advanced discovery of penicillin by Alexander Fleming in 1928, prescription antibiotics have been an essential tool in the battle against germs and infections. And although we still use the same tested methods today, germs have progressed. When exposed to prescription antibiotics, certain germs, fungis and parasites are able to adapt and cancel the efficiency of the drug by establishing resistance.

It’s worth explaining that antimicrobial resistance was most likely to take place anyway, as the hereditary code for germs changes over time. However, it is thought that the overuse of prescription antibiotics is an important element that accelerates the advancement of resistant strains.

According to the World Health Organization, antimicrobial resistance “is a significantly major hazard to global public health that requires action in all sectors of government and in society.” This has led scientists to believe outside package by trying to determine compounds that could be helpful in the battle against damaging germs. One of these compounds is cannabidiol (CBD), a cannabinoid discovered in Cannabis sativa.

Researchers are looking for new methods to assault infections and resistant germs.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that CBD works against Gram-positive germs. Strains of Gram-positive germs include Staphylococcus aureus (typical in skin infections) and Streptococcus pneumoniae (typical in bacterial pneumonia).

Dr. Blaskovich presented his findings at an annual conference of the American Society for Microbiology. In vitro samples of both types of gram-positive germs were treated with artificial CBD. The outcomes led Dr. Blaskovich to the conclusion that CBD works at levels comparable to those of prescription antibiotics vancomycin and daptomycin. He also found that CBD appeared to work against gram-positive strains of resistant germs, which numerous traditional prescription antibiotics are starting to fail.

” In specific, the activity was selected against the resistant strains of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low tendency to induce resistance and was active against MRSA biofilms. “

The group also carried out another study utilizing topical CBD to deal with a skin infection in mice. Once again, although the outcomes were positive, CBD did not appear to eliminate the infection, however simply to reduce the number of bacterial cells.

Could CBD become an antibiotic?

While it is easy to hail this work as a significant development in the anti-bacterial capabilities of CBD, it is too soon to give up on penicillin.

Although it is thought that the efficiency of eureka CBD might originate from the way it attacks the biofilm surrounding bacterial cells, the authors are still unsure of the system of action of CBD. They also did not hesitate to explain the imperfections of the study. Dr. Blaskovich mentioned that given that the outcomes are in the initial stages, it is far prematurely for people to begin treating their CBD infections themselves.

The study was also carried out in vitro (outside the body), and there is a risk that the outcomes of scientific trials will not be the same. Numerous compounds have shown anti-bacterial effectiveness in petri meals, however then failed at this essential phase. It should also be pointed out that the two research studies were carried out in collaboration with Botanix Pharmaceuticals Ltd, a pharmaceutical business focusing on topical provision CBD products.

However, this research study could be an important advance for CBD and the battle against antimicrobial resistance.

Scroll to top